CCR2 and primary progressive multiple sclerosis: This study investigated the expression of CTLA-4 and FOXP3 in CD4+CD25+ Treg cells, and CD40 and CD192 in monocyte subpopulations in PPMS (ocrelizumab treated and untreated) subjects compared to healthy controls.